Good news and bad news in biotech IPO market

07/23/2013 | Xconomy

The market for biotech initial public offerings has rebounded this year, spurred by generalist investors who previously shunned the industry, but the party won't last long, Luke Timmerman writes. Neglected diseases will get a boost, as will regional innovation hubs, and small companies will gain negotiating leverage, but some investors will lose interest after they lose money, Timmerman writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ